A landmark $64 million pharmaceutical manufacturing facility in Christ Church, Barbados, is moving rapidly toward realization after two binding collaborative agreements were formalized at the recent Commonwealth Business Forum hosted in Antigua and Barbuda, marking a major milestone for the island’s industrial and public health infrastructure. Slated for development within the Grantley Adams Industrial Estate, the state-of-the-art plant will boast an annual production capacity of 12 million bags of intravenous (IV) fluids, designed first to meet local domestic demand before expanding distribution across Caribbean regional export markets. The core partnership driving the project brings together Barbadian entity Barbados Pharmaceutical Inc. (BPI) and Nigeria’s AMA Medical Manufacturing, with the pair signing a formal memorandum of understanding (MoU) during the high-profile forum to codify their joint venture framework. The signing ceremony was overseen by key regional and national leaders, including Barbadian Prime Minister Mia Mottley and Nigeria’s Secretary to the Government of the Federation Senator George Akume, with BPI acting CEO Dr. Cindi Lewis and African Medicines Agency Chairman Abdullahi Musa Bello executing the official partnership paperwork. A complementary second agreement was also inked between AMA and the African Export-Import Bank (Afreximbank), unlocking dedicated technical support and structured financial planning resources to shepherd the project through pre-investment due diligence and preparatory phases. BPI leadership emphasized that the core mission of the new facility is to slash the Caribbean’s longstanding overreliance on imported IV fluids, which has left regional healthcare systems vulnerable to global supply chain disruptions, while fortifying consistent access to life-saving essential medical supplies for local populations. The project is projected to create over 200 direct full-time jobs for Barbadians, with structured upskilling pathways to equip local workers with specialized, globally competitive expertise in pharmaceutical production, rigorous quality assurance protocols, and adjacent technical operational fields. Under the terms of the agreed joint venture, AMA will take the lead on end-to-end facility design, construction oversight, and day-to-day operational management once the plant is commissioned, while BPI will leverage its local networks to secure land tenure, navigate domestic pharmaceutical regulatory frameworks, streamline market entry across Caribbean jurisdictions, and sustain ongoing close engagement with the Barbadian government. This $64 million IV fluids facility is the first tangible output of a far broader national strategy to build a full-fledged domestic pharmaceutical manufacturing sector in Barbados, a vision first unveiled by Prime Minister Mottley back in November 2022 following high-level bilateral discussions with Rwandan government counterparts. At that initial announcement, Mottley projected the wider industry could generate between 4,000 and 5,000 skilled local jobs within a four to five year timeline, with long-term ambitions to expand production portfolios to include life-saving vaccines, targeted cancer therapies, and critical women’s reproductive health medications. Progress on that strategic vision accelerated in November 2023, when Barbados received a formal Biopharma White Book that mapped out the full regulatory and compliance groundwork required to bring the nation’s pharmaceutical sector in line with stringent international manufacturing standards. This foundational industry development initiative has been executed in close trilateral cooperation with Rwanda and Guyana, to align regional regulatory norms and create a unified cross-border market for locally produced medical supplies. The impetus for building domestic production capacity across the Caribbean was sharpened by widespread systemic failures witnessed during the COVID-19 pandemic, when nations across the region faced crippling delays and shortages of essential medicines, vaccines, and critical medical equipment even when they had allocated sufficient public funding to procure the supplies on global markets. The formal partnership with Nigeria took concrete shape in November 2025, when the two national governments signed a sweeping bilateral agreement covering cross-border pharmaceutical manufacturing collaboration, workforce skills development, coordinated regional and continental market access, and harmonized regulatory alignment. That intergovernmental pact built on months of prior exploratory discussions between Barbados and AMA Medical Manufacturing to establish a regional production hub on Barbadian soil. While the two newly signed agreements mark a critical inflection point for the IV fluids plant project, formal financing finalization and a slate of remaining pre-construction preparatory tasks will need to be completed before ground can be broken on the new industrial facility.